GlassScriptPhysician profile
Sarah Maddison
NPI 1548220197
$6,523.37
in general payments reported to CMS, 2019-2025
52 companies · $1,170 in 2025
The $1,170 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $357 · 2021: $1,229 · 2022: $901 · 2023: $1,513 · 2024: $970 · 2025: $1,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,236 · Consulting Fee: $300 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,235.85 |
| Consulting Fee | $300.00 |
| Education | $116.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $678.47 | 2021-2025 | |
| Abbvie INC. | $642.15 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $624.73 | 2019-2025 | |
| Astellas Pharma US INC | $613.63 | 2019-2025 | Veozah, Myrbetriq |
| Evofem Biosciences, INC. | $316.46 | 2020-2025 | Phexxi, Solosec, Phexx |
| Myriad Women'S Health, INC. | $300.00 | 2023 | Myrisk |
| Pfizer INC. | $298.85 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $275.00 | 2021 | |
| Novo Nordisk INC | $262.09 | 2022-2025 | Wegovy |
| Organon LLC | $249.96 | 2022-2025 | Nexplanon |
| Biogen, INC. | $222.09 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $190.40 | 2019-2024 | Paragard T 380a, Endosee |
| Daiichi Sankyo INC. | $163.45 | 2019-2022 | |
| Therapeuticsmd, INC. | $147.28 | 2019-2021 | |
| Avion Pharmaceuticals | $134.78 | 2021-2022 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $132.40 | 2023-2025 | Myfembree, Gemtesa |
| Agile Therapeutics, INC. | $128.50 | 2022-2023 | Twirla |
| Shield Therapeutics INC | $112.20 | 2023-2025 | Accrufer |
| Exact Sciences Corporation | $85.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $71.75 | 2019-2021 | |
| Myovant Sciences INC. | $60.86 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.44 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $52.80 | 2021 | |
| Vertical Pharmaceuticals, LLC | $48.24 | 2019 | |
| Medtronic, INC. | $45.12 | 2021 | |
| Millicent US INC | $44.45 | 2024 | Femring, Intrarosa |
| Channel Medsystems, INC. | $41.69 | 2023 | |
| Lupin INC. | $39.08 | 2020-2021 | |
| Lilly USA, LLC | $38.12 | 2023-2024 | Zepbound |
| Mylan Pharmaceuticals INC. | $35.62 | 2021 | |
| Exeltis, USA INC. | $32.48 | 2024-2025 | Slynd |
| Covidien LP | $32.43 | 2019-2020 | |
| Zyla Life Sciences, INC. | $32.41 | 2019-2020 | |
| Seqirus USA INC | $27.85 | 2024 | Fluad, Flucelvax |
| Amag Pharmaceuticals, INC. | $24.88 | 2019-2020 | |
| Roche Diagnostics Corporation | $24.64 | 2019 | |
| Agios Pharmaceuticals, INC. | $22.31 | 2023 | Pyrukynd |
| Abbott Laboratories | $21.05 | 2024 | Freestyle Libre 3 |
| Duchesnay USA Incorporated | $17.59 | 2019 | |
| Trevena, INC. | $16.92 | 2021 | |
| Hologic Sales and Service, LLC | $16.85 | 2024 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Urovant Sciences INC | $16.46 | 2021 | |
| Sage Therapeutics, LLC | $16.36 | 2022 | |
| Terumo Medical Corporation | $15.83 | 2021 | |
| Solventum Corporation | $14.17 | 2025 | Prevena |
| Scynexis, INC. | $13.94 | 2021 | |
| Medicem INC. | $13.76 | 2021 | |
| Amgen INC. | $13.05 | 2020 | |
| Boston Scientific Corporation | $11.69 | 2019 | |
| Minerva Surgical, INC | $11.68 | 2022 | |
| Meditrina | $10.81 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Maddison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.